Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Endocrinology | US/EU | 2020

Login to access report north_east
Contact sales account_box

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin lispro Sanofi. Subsequently, the EC approved Biocon / Mylan’s insulin glargine biosimilar, Semglee, which the FDA approved in June 2020.

The prescribing behavior of endocrinologists will directly impact the uptake of these products, including insulin brands such as Sanofi’s Lantus and Eli Lilly’s Humalog. Understanding physicians’ attitude and behavior toward biosimilars / follow-on insulins is critical for development and marketing strategies aimed at persuading endocrinologists to prescribe and drive biosimilar / follow-on insulin uptake.

DRG’s primary research with endocrinologists in the United States, France, and Germany allows clients to assess the dynamics determining current and future biosimilar / follow-on insulin uptake within the diabetes space.

This report includes the following topics:

  • Physicians’ current experience prescribing biosimilars / follow-on insulins.
  • The main drivers and barriers influencing biosimilar / follow-on insulin uptake.
  • The impact of cost and clinical data on biosimilar / follow-on insulin uptake.

Scope

Markets covered: United States, France, and Germany.

Primary research: Online quantitative survey of 91 endocrinologists.

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east